非小细胞肺癌脑转移的药物治疗进展

Research progress of drug therapy for brain metastasis from non-small cell lung cancer

肺癌发病率和病死率高,最常见的病理类型为非小细胞肺癌,24%~40%的晚期非小细胞肺癌患者出现脑转移,预后不良。手术治疗以及传统放疗效果并不理想,血脑屏障也阻碍了化疗药物发挥其疗效。近年来,靶向药物及免疫治疗的出现为非小细胞肺癌脑转移患者提供了新的治疗希望,该文就目前非小细胞肺癌脑转移患者的药物治疗方式展开了全面综述,比较各类药物单用及联用的临床疗效,为非小细胞肺癌脑转移患者提供更合理的治疗方案建议。

The morbidity and mortality of lung cancer are high.And the most common pathological type is non-small cell lung cancer.24%-40%of the patients with advanced non-small cell lung cancer develop brain metastases with poor prognosis.Traditional radiotherapy and surgery are not effective for patients with brain metastases of non-small cell lung cancer.And chemotherapy drugs also have difficulty working because of the blood brain barrier.In recent years,the advances of targeted drugs and immunotherapy have provided a new hope for the treatment of patients with brain metastases from non-small cell lung cancer.The current advances of drug therapy in patients with brain metastases from non-small cell lung cancer will be introduced in this article.Comparison of the various drugs efficacy alone and in combination will be introduce as well,in order to provide a more reasonable treatment for patient with brain metastases from non-small cell lung cancer.